Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)
1.490
+0.070 (4.93%)
Jul 3, 2026, 3:04 PM CST
SHE:000078 Revenue
Shenzhen Neptunus Bioengineering had revenue of 5.95B CNY in the quarter ending March 31, 2026, a decrease of -19.39%. This brings the company's revenue in the last twelve months to 25.24B, down -14.75% year-over-year. In the year 2025, Shenzhen Neptunus Bioengineering had annual revenue of 26.67B, down -12.04%.
Revenue (ttm)
25.24B
Revenue Growth
-14.75%
P/S Ratio
0.16
Revenue / Employee
3.75M
Employees
6,734
Market Cap
3.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.67B | -3.65B | -12.04% |
| Dec 31, 2024 | 30.32B | -6.10B | -16.75% |
| Dec 31, 2023 | 36.42B | -1.42B | -3.74% |
| Jan 1, 2023 | 37.83B | -3.22B | -7.84% |
| Jan 1, 2022 | 41.05B | 1.03B | 2.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.16B |
| Jinhe Biotechnology CO., LTD. | 2.99B |
| Nanjing Well Pharmaceutical Group | 1.34B |
| Tibet Weixinkang Medicine | 1.16B |
| LanZhou Foci Pharmaceutical | 910.98M |
| Shandong Wohua Pharmaceutical | 818.16M |
| Newland Pharmaceutical | 659.54M |
| Shanghai Xiao Fang Pharmaceutical | 541.90M |